Endovascular interventional therapy is a cornerstone in the management of cardioembolic stroke , though neurological injury from post-ischemic inflammation and oxidative stress remains a challenge. Diterpene Ginkgolides Meglumine Injection (DGMI), a Ginkgo biloba–derived neuroprotective agent, has shown antiplatelet, anti-inflammatory, and antioxidant effects but has been minimally studied alongside endovascular treatment. To address this gap, a study evaluated the efficacy of Diterpene Ginkgolides Meglumine Injection as an adjunct to endovascular therapy in 104 patients with cardioembolic stroke.
The study found that patients in the DGMI treatment group had significantly better outcomes than controls, with lower Preoperative National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin Scale (mRS) scores at 14 days and a lower mRS score at 90 days. Logistic regression…
